Molecular docking and binding mode analysis of selected FDA approved drugs against COVID-19 selected key protein targets: An effort towards drug repurposing to identify the combination therapy to combat COVID-19
원문 초록
The emergence of COVID-19 has severely compromised the arsenal of antiviral and antibiotic drugs. Drug discovery is a multistep process with a high failure rate, high cost and it takes approximately 10-12 years for the development of new molecules into the clinical candidate. On the other side, drug repurposing also called old drugs for new uses, is an attractive alternative approach for a new application of marketed FDA approved or investigational drugs. In the current pandemic situation raised due to COVID-19, repurposing of existing FDA approved drugs are emerging as the first line of the treatment. The causative viral agent of this highly contagious disease and acute respiratory syndrome coronavirus (SARS-CoV) shares high nucleotide similarity. Therefore, many existing viral targets are structurally expected to be similar to SARS-CoV and likely to be inhibited by the same compounds. Here, we selected three viral key proteins based on their vital role in viral life cycle: ACE2 (helps in entry into the human host), viral nonstructural proteins RNA-dependent RNA polymerase (RdRp) NSP12, and NSP16 which helps in replication, and viral latency (invasion from immunity). The FDA approved drugs chloroquine (CQ), hydroxychloroquine (HCQ), remdesivir (RDV) and arbidol (ABD) are emerging as promising agents to combat COVID-19. Our hypothesis behind the docking studies is to determine the binding affinities of these drugs and identify the key amino acid residues playing a key role in their mechanism of action. The docking studies were carried out through Autodock and online COVID-19 docking server. Further studies on a broad range of FDA approved drugs including few more protein targets, molecular dynamics studies, in-vitro and in-vivo biological evaluation are required to identify the combination therapy targeting various stages of the viral life cycle.
함께 살펴볼 논문
공통 태그를 근거로 연결했습니다. 실제 인용 관계나 논문의 우수성을 뜻하지 않습니다.
PocketVina Enables Scalable and Highly Accurate Physically Valid Docking through Multi-Pocket Conditioning
Fast and Accurate Blind Flexible Docking
Q-Score: 분자 도킹을 위한 양자 네이티브 스코어링 함수
Q-Score: A Quantum-Native Scoring Function for Molecular Docking
분자 도킹은 소분자가 단백질에 결합하는 방식을 예측하며, 신약 개발의 핵심 병목 단계이다. 고전적인 스코어링 함수는 경험적 쌍별 접촉을 합산하는 방식으로, 결합 특이성을 결정하는 궤도 전하 이동과 같은 양자역학적 효과를 반영하지 못한다. 본 연구에서는 Q-Score를 제안한다. Q-Score는 GNN으로 예측된 궤도 전자 공여-수용 에너지를 가중 그래프로 인코딩하고, Digitized-Counterdiabatic QAOA를 통해 최대 가중치 정점 클리크 문제를 풀어 결합을 스코어링한다. 각 상호작용 앵커는 하나의 큐비트에 대응되며, 호환성 제약 조건은 에지로 표현된다. 11개의 단백질 타겟에 대해 DC-QAOA는 10큐비트에서 8개의 타겟에서 정확한 최적해를 복원한다. AI 생성 분자 1,000개에 대해 Q-Score는 Spearman rho 0.05로 고전적 스코어링과 직교하며, rho 0.90으로 궤도 품질에 의해 주도되고, 분자량 바이어스가 없으며, 무작위 대비 두 배의 비율로 강한 궤도 상호작용을 농축시킨다. DC-QAOA는 52%의 정확률과 함께 평균 근사 비율 0.94를 달성한다. IBM Eagle에서 1,000개의 회로 실행을 통해 NISQ 하드웨어상 6큐비트 문제의 해결 가능성이 확인되었다.
In Silico Prediction and Validation of LmGt Inhibitors Using QSAR and Molecular Docking Approaches
Enhancing Chemical Reaction and Retrosynthesis Prediction with Large Language Model and Dual-task Learning
Optimization of binding affinities in chemical space with generative pretrained transformer and deep reinforcement learning
토론
이 논문과 연결된 포럼 글이 아직 없습니다.